Rosiglitazone

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 3, 2001, Pages 467-478

  Wolffenbuttel, B H R ^a   Sels, J P ^a   Huijberts, M S P ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Rosiglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE; CELL NUCLEUS RECEPTOR; CIGLITAZONE; DARGLITAZONE; ENGLITAZONE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIET THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; LIVER TOXICITY; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MICROALBUMINURIA; MICROVASCULARIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEPTOR INTRINSIC ACTIVITY; SIDE EFFECT;

ANIMALS; BLOOD PRESSURE; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; METFORMIN; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035021221     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.3.467     Document Type: Article

References (42)

1. The triumvirate: β-cell, muscle, liver: A collusion responsible for NIDDM
2. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus
3. Pathogenesis of NIDDM. A balanced overview
4. Hyperglycaemia as an inducer as well as consequence of impaired islet cell function and insulin resistance: Implications for the management of diabetes
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33)
6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34)
7. Thiazolidinediones: A new class of antidiabetic drugs
8. Islet amyloid and Type 2 diabetes mellitus
9. Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: Relation to insulin action
10. The hormone resistin links obesity to diabetes
11. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
12. BRL 49653 blocks the lipolytic actions of tumour necrosis factor-α: A potential new insulin-sensitizing mechanism for thiazolidinediones
13. Troglitazone effects on gene expression in human skeletal muscle of Type II diabetes involve upregulation of peroxisome proliferator-activated receptor-γ
14. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese Type II diabetic subjects
15. Troglitazone action is independent of adipose tissue
16. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists
17. v- and t-SNARE protein expression in models of insulin resistance - Normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2 and of Zucker diabetic fatty rats
18. Differential activation of peroxisome proliferator-activated receptor-γby troglitazone and rosiglitazone
19. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production
20. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling
21. Rosiglitazone monotherapy improves glycaemic control in patients with Type 2 diabetes: A twelve-week, randomized, placebo-controlled study
22. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes
23. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus
24. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
25. Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: A randomized controlled trial
26. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated Type 2 diabetes
27. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
28. Intact pro-insulin and β-cell function in lean and obese subjects with and without Type 2 diabetes
29. Rosiglitazone decreases insulin resistance and improves β-cell function in patients with Type 2 diabetes
30. Homeostasis model assessment: Insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man
31. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
32. Rosiglitazone improves blood pressure in patients with Type 2 diabetes mellitus
33. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones
34. Troglitazone-induced fulminant hepatic failure
35. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures
36. Hepatic failure in a patient taking rosiglitazone
37. Hepatocellular injury in a patient receiving rosiglitazone. A case report
38. Correction: Liver injury and rosiglitazone
39. Prospective study of serum γ-glutamyltransferase and risk of NIDDM
40. Rosiglitazone reduces hepatic fat content
41. Cholesterol and coronary heart disease: Predicting risks by levels and ratios
42. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): Prospective observational study